Neurotoxicity
neurotoxicity
Advances and setbacks in prion biology
Transmissible spongiform encephalopathies (TSEs) are neurodegenerative diseases of humans and many animal species caused by prions. The main constituent of prions is PrPSc, an aggregated moiety of the host-derived membrane glycolipoprotein PrPC. Prions were found to encipher many phenotypic, genetically stable TSE variants. The latter is very surprising, since PrPC is encoded by the host genome and all prion strains share the same amino acid sequence. Here I will review what is known about the infectivity, the neurotoxicity, and the neuroinvasiveness of prions. Also, I will explain why I regard the prion strain question as a fascinating challenge – with implications that go well beyond prion science. Finally, I will report some recent results obtained in my laboratory, which is attempting to address the strain question and some other basic issues of prion biology with a “systems” approach that utilizes organic chemistry, photophysics, proteomics, and mouse transgenesis.
Neurotoxicity is a major health problem in Africa: focus on Parkinson's / Parkinsonism
Parkinson's disease (PD) is the second most present neurodegenerative disease in the world after Alzheimer's. It is due to the progressive and irreversible loss of dopaminergic neurons of the substantia nigra Pars Compacta. Alpha synuclein deposits and the appearance of Lewi bodies are systematically associated with it. PD is characterized by four cardinal motor symptoms: bradykinesia / akinesia, rigidity, postural instability and tremors at rest. These symptoms appear when 80% of the dopaminergic endings disappear in the striatum. According to Braak's theory, non-motor symptoms appear much earlier and this is particularly the case with anxiety, depression, anhedonia, and sleep disturbances. In 90 to 95% of cases, the causes of the appearance of the disease remain unknown, but polluting toxic molecules are incriminated more and more. In Africa, neurodegenerative diseases of the Parkinson's type are increasingly present and a parallel seems to exist between the increase in cases and the presence of toxic and polluting products such as metals. My Web conference will focus on this aspect, i.e. present experimental arguments which reinforce the hypothesis of the incrimination of these pollutants in the incidence of Parkinson's disease and / or Parkinsonism. Among the lines of research that we have developed in my laboratory in Rabat, Morocco, I have chosen this one knowing that many of our PhD students and IBRO Alumni are working or trying to develop scientific research on neurotoxicity in correlation with pathologies of the brain.
CB1R activation decreases NMDA-induced neurotoxicity in APPSw/Ind mice model of AD
FENS Forum 2024
Ferulic acid supplementation ameliorates lindane neurotoxicity: The effects on anxiety-like behavior
FENS Forum 2024
Glucocerebrosidase pharmacological chaperones attenuate α-synuclein-induced neurotoxicity in chronic cortico-striatal slices
FENS Forum 2024
Impact of the AT8 epitope phosphorylation on Tau aggregation, propagation, and neurotoxicity
FENS Forum 2024
Intracisternal RAD-IGF1 reduces anxiety-like behavior in a rat model of neurotoxicity induced by 6-OHDA
FENS Forum 2024
miR-302 induced by glucagon-like peptide-1 (GLP-1) signaling reduces the α-synuclein neurotoxicity linked to dementia with Lewy bodies (DLB)
FENS Forum 2024
Neurotoxicity of Cumyl-PINACA synthetic cannabinoid: Involvement of multiple cannabinoid receptors
FENS Forum 2024
NMDAR-TRPM4 coupling drives neurotoxicity and disease progression in models of spinocerebellar ataxias
FENS Forum 2024
Post-treatment approach for hypoxia and ischemia: Selective targeting of non-nuclear estrogen receptors signaling pathway inhibits neurotoxicity and apoptosis
FENS Forum 2024
Transcriptomic characterization of maturing neurons from human neural stem cells across developmental time points and their application in developmental neurotoxicity screening
FENS Forum 2024
In vitro modelling of immune effector cell-associated neurotoxicity syndrome (ICANS) resulting from CAR T-cell therapy treating haematological cancer
FENS Forum 2024